CCK receptor

亜型選択性的な製品

CCKB

CCK receptor製品

All (7)
CCK receptor阻害剤 (1)
CCK receptor抗体(1)
CCK receptor活性剤(1)
CCK receptor拮抗剤(1)
CCK receptor作動薬(1)
CCK receptorモジュレータ(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2032	Rebamipide	Rebamipide (OPC-12759,Proamipide) is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [¹²⁵I]BH-CCK-8S with IC50 of 37.7 μM.	Signal Transduct Target Ther, 2021, 6(1):148 University of Alberta, 2014, Yahya Muhammad Fiteih
P1249	Gastrin I, human	Gastrin I, human is an important analogue of gastrin, an endogenous gastrointestinal peptide hormone. It plays key roles in digestion and energy homeostasis via CCK2 receptor activation in digestive processes including gastric acid secretion, pancreatic enzyme release, gallbladder emptying, gut motility.
S9690	Caerulein (FI-6934)	Caerulein (Ceruletide, Cerulein, FI-6934), a cholecystokinin (CCK) receptor agonist, is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.Caerulein (FI-6934) can be used to induce animal models of Acute pancreatitis.	J Adv Res, 2025, S2090-1232(25)00225-5 J Gastroenterol, 2025, 10.1007/s00535-025-02323-y
E7316	Cholecystokinin Octapeptide, desulfated	Cholecystokinin Octapeptide, desulfated, (CCK-8 (desulphated)) is a synthetic peptide lacking the sulfate group on its tyrosine residue, reducing its activity at CCK-A receptors while allowing selective binding to CCK-B receptors. It is used in research to study central and gastric effects mediated by CCK-B receptors, independent of digestive enzyme stimulation.
S6939	Nastorazepide	Nastorazepide (Z-360), a cholecystokinin-2/gastrin receptor (CCK2/gastrin receptor) antagonist, combines with gemcitabine prolonged survival and reduces gemcitabine-induced vascular endothelial growth factor (VEGF) expression in a pancreatic carcinoma orthotopic xenograft mouse.
A2803	Cofetuzumab (Anti-PTK7 / CCK4)	Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD.
S9690	Caerulein (FI-6934)	Caerulein (Ceruletide, Cerulein, FI-6934), a cholecystokinin (CCK) receptor agonist, is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.Caerulein (FI-6934) can be used to induce animal models of Acute pancreatitis.	J Adv Res, 2025, S2090-1232(25)00225-5 J Gastroenterol, 2025, 10.1007/s00535-025-02323-y
S2032	Rebamipide	Rebamipide (OPC-12759,Proamipide) is a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [¹²⁵I]BH-CCK-8S with IC50 of 37.7 μM.	Signal Transduct Target Ther, 2021, 6(1):148 University of Alberta, 2014, Yahya Muhammad Fiteih
A2803	Cofetuzumab (Anti-PTK7 / CCK4)	Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD.
P1249	Gastrin I, human	Gastrin I, human is an important analogue of gastrin, an endogenous gastrointestinal peptide hormone. It plays key roles in digestion and energy homeostasis via CCK2 receptor activation in digestive processes including gastric acid secretion, pancreatic enzyme release, gallbladder emptying, gut motility.
S6939	Nastorazepide	Nastorazepide (Z-360), a cholecystokinin-2/gastrin receptor (CCK2/gastrin receptor) antagonist, combines with gemcitabine prolonged survival and reduces gemcitabine-induced vascular endothelial growth factor (VEGF) expression in a pancreatic carcinoma orthotopic xenograft mouse.
S9690	Caerulein (FI-6934)	Caerulein (Ceruletide, Cerulein, FI-6934), a cholecystokinin (CCK) receptor agonist, is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.Caerulein (FI-6934) can be used to induce animal models of Acute pancreatitis.	J Adv Res, 2025, S2090-1232(25)00225-5 J Gastroenterol, 2025, 10.1007/s00535-025-02323-y
E7316	Cholecystokinin Octapeptide, desulfated	Cholecystokinin Octapeptide, desulfated, (CCK-8 (desulphated)) is a synthetic peptide lacking the sulfate group on its tyrosine residue, reducing its activity at CCK-A receptors while allowing selective binding to CCK-B receptors. It is used in research to study central and gastric effects mediated by CCK-B receptors, independent of digestive enzyme stimulation.